Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Bromantane
Bromantane is an adamantane derivative with stimulant, anxiolytic, and nootropic properties. Developed as a Russian pharmaceutical in the late 1980s and sold as Ladasten, it is approved in Russia for treating neurasthenia. It is an atypical central nervous system stimulant related to amantadine and memantine, with effects distinct from typical stimulants such as amphetamine. It is regarded in the literature as an actoprotector that can increase physical performance1.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Pharmacology
Pharmacodynamics
In rats receiving 50 mg/kg orally, bromantane affected brain dopamine parameters, suggesting an important role for the dopaminergic system in its pharmacological effects2. Bromantane enhances dopaminergic neurotransmission indirectly by increasing expression of tyrosine hydroxylase and aromatic L-amino acid decarboxylase, which promotes de novo dopamine synthesis. In rats, a single dose produced a reported 2-2.5-fold increase in tyrosine hydroxylase expression, with corresponding increases in dopamine biosynthesis and release in several brain regions; the relevance of some longer-term gene-expression findings to humans is unclear. Bromantane may also strengthen GABAergic mediation and has been reported to inhibit serotonin, dopamine, and, to a lesser extent, norepinephrine reuptake in rat brain tissue at very high concentrations that are likely not clinically relevant. Its precise direct molecular mechanism remains unknown, and sigma-1 receptor involvement has been proposed by structural analogy to related adamantanes.
Pharmacokinetics
Reported bioavailability is 42%, although the cited value is not assigned to a specific route. After oral administration, maximum blood concentrations were reached at 2.75 hours in women and 4 hours in men, with a higher absorption rate reported in women.1 The main reported metabolite is 6β-hydroxybromantane.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Harm Potential
Toxicity
In animals, very high doses produce antimuscarinic and antinicotinic effects that are responsible for toxicity reflected in LD50 measurements; these effects are not relevant at clinical dosages.
Very high doses in animals produce anticholinergic toxicity through antimuscarinic and antinicotinic effects.
History & Culture
Development and Soviet military use
Bromantane was developed during the 1980s at the Zakusov State Institute of Pharmacology of the USSR Academy of Medical Sciences in Moscow. Researchers designed it as a psychoactivating and adaptogenic drug for demanding conditions such as hypoxia, high temperatures, physical overexertion, and…
Legality
By Country
References
Source Pages
Citations
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Bromantane article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.